Tumor Biomarkers And Clinical Applications In Colorectal Cancer | 25220
Journal of Gastrointestinal & Digestive System
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Tumor biomarkers play an important role in the detection and management of patients with malignant cancer, including
colorectal cancer. Recent studies indicated that the prevention and treatment will achieve a strategic breakthrough if
tumors can be found at early stage. Therefore, improved methods for early detection and disease monitoring are urgently
needed. Currently, a variety of technology platforms are used in biomarker discovery, such as genomics, proteomics, and
metabolomics as well as bioinformatics, nanotechnology. These biomarkers may be methylated DNA, a change in the
metabolism of proteins, and mRNA, miRNA or lncRNA changes which are closely associated with the disease progression.
To distinguish colorectal cancer from benign colorectal diseases, we found that serum sHLA-G level was significantly higher
in colorectal cancer compared to normal colorectum, hyperplastic polyp, inflammational bowl diseases and adenoma. In
addition, with the proteomics technology, we identified the protein ORM2 as a serum differential marker by Q-TOF-MS.
The recent discovery of serum miRNA profile in human cancer has provided a new auxiliary approach for tumor diagnosis.
Furthermore, by solex sequencing and the selection and validation process via RT-qPCR, we identified a 4-miRNA panel with a
high diagnostic accuracy of colorectal adenocarcinoma. In this article, we evaluated the current possibilities and limitations of
molecular biomarker in routine clinical practice, summarized a number of potential biomarkers that are involved in colorectal
cancer with our own research by both clinical investigations and basic mechanism studies, and also discussed how multiple
omics researches lead to many new candidate biomarkers.
Chuanxin Wang has completed his PhD from School of Medicine, Shandong University. A senior visiting scholar in the University of California, San Francisco in
2008; honored as ?outstanding experts of China laboratory medicine? in 2009. He is the director of Clinical Laboratory Medicine Center, Qilu Hospital of Shandong
University; the young expert with outstanding contributions, Ministry of Health and also Chairman of Association of Clinical laboratory Medicine. His research
interstes include tumor diagnosis, personalized treatment and translational medicine. He has gained grants from National Natural Science Foundation Project,
National 863 project, Chinese Academy of Medical Science Project, and so on. He has published more than 30 papers about tumor related articles by his research
group during the recent three years.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals